Skip to content
10-K

Annual Report

GALECTIN THERAPEUTICS INC GALT

0001140361-26-012155

← back to feed
Filed
Mar 31, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 2, 2026 65.83M sh
Shares Diluted FY 2025 · Dec 31, 2025 63.9M sh
Shares Diluted FY 2025 · Dec 31, 2024 62.31M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$23.88M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$41.77M
Cash And Equivalents FY 2025 · Dec 31, 2025 $17.72M
Cash And Equivalents FY 2025 · Dec 31, 2024 $15.12M
Stockholders Equity FY 2025 · Dec 31, 2025 −$127.92M
Stockholders Equity FY 2025 · Dec 31, 2024 −$104.79M
Stockholders Equity FY 2025 · Dec 31, 2023 −$61.96M
Current Liabilities FY 2025 · Dec 31, 2025 $8.03M
Current Liabilities FY 2025 · Dec 31, 2024 $35.41M
Total Liabilities FY 2025 · Dec 31, 2025 $145.73M
Total Liabilities FY 2025 · Dec 31, 2024 $120.57M
Current Assets FY 2025 · Dec 31, 2025 $19.44M
Current Assets FY 2025 · Dec 31, 2024 $17.25M
Total Assets FY 2025 · Dec 31, 2025 $19.53M
Total Assets FY 2025 · Dec 31, 2024 $17.5M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.48
Eps Diluted FY 2025 · Dec 31, 2024 −$0.76
Eps Basic FY 2025 · Dec 31, 2025 −$0.48
Eps Basic FY 2025 · Dec 31, 2024 −$0.76
Sga Expense FY 2025 · Dec 31, 2025 $5.8M
Sga Expense FY 2025 · Dec 31, 2024 $5.86M
Rd Expense FY 2025 · Dec 31, 2025 $14.29M
Rd Expense FY 2025 · Dec 31, 2024 $36.57M
Net Income FY 2025 · Dec 31, 2025 −$30.84M
Net Income FY 2025 · Dec 31, 2024 −$47.05M
Operating Income FY 2025 · Dec 31, 2025 −$20.09M
Operating Income FY 2025 · Dec 31, 2024 −$42.43M